Navigation Links
Boehringer Ingelheim's interferon-free hepatitis C treatment portfolio strengthened by promising interim Phase 2a data
Date:11/2/2013

RIDGEFIELD, Conn., Nov. 2, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced interim data from its Phase 2a hepatitis C (HCV) clinical collaboration (NCT01859962) with Presidio Pharmaceuticals, Inc. that showed all patients (13/13) who reached the 4-week post-treatment follow-up had undetectable levels of hepatitis C virus (SVR4) with an investigational, 12-week, all-oral regimen of faldaprevir and deleobuvir, in combination with Presidio's pan-genotypic NS5A inhibitor, PPI-668, with ribavirin. The primary efficacy endpoint of this ongoing trial is sustained virologic response 12 weeks after completion of treatment (SVR12).

An additional study arm evaluating the regimen without ribavirin, which was added per protocol following initial results in the ribavirin-containing arms, showed that after four weeks on treatment, 12/12 patients had hepatitis C virus levels below an amount that can be quantified (LLOQ).  

These data are being presented during the late-breaking poster session at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place in Washington, D.C.

"We continue to be encouraged by the preliminary results of this investigational triple combination of direct-acting antivirals in patients with genotype-1a HCV, and in particular that, at this stage, the ribavirin-free combination has yielded similar results to the ribavirin-containing arms of the trial," said Jacob Lalezari, M.D., director of Quest Clinical Research in San Francisco, CA.

This ongoing Phase 2a study evaluates 36 treatment-naive genotype-1a HCV patients. Two thirds of patients have the difficult-to-treat CT or TT IL28B genotype. Previous studies have shown that presence of
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...  Lockton Dunning Benefits, the Dallas ... addition of Vice President Kim Foerster ... Consulting team, Excelsior Solutions. Foerster ... the position.  Most recently, she worked as the ... Pharmacy, where she has held various managerial positions ...
(Date:12/24/2014)...  Medical Science Liaisons play a large role in ... medical device industry and key stakeholders, the role of ... as the device industry relies on them to build ... benchmarking firm, Best Practices, LLC, one area where Medical ... by harnessing new technology to enable education. Online conferences ...
(Date:12/22/2014)... --  TRU-D SmartUVC LLC, producers of the first ... that the General Services Administration has awarded the company ... This newly formed agreement will allow TRU-D SmartUVC ... including Department of Veteran Affairs and Department of Defense ... solutions for the Ebola effort in West ...
Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2Role of Medical Science Liaisons Evolving in Medical Device Sector 2TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2
... CoreLab Partners, Inc. has launched a new ... Medical Parameters for Solutions (A.M.P.S.) LLC. "We ... semi-automated CalECG v3 solution for the analysis of ECGs," ... Mike Woehler. "This new application represents our commitment to ...
... (ECIA:PK), a medical device company owning patented surgical technology that ... reported its financial results for its second fiscal quarter ended ... loss of $469,000 or $(0.07) per share for the second ... $2.830 million and net service revenue of $437 thousand. Total ...
Cached Medicine Technology:CoreLab Partners Now Offers Semi-automated ECG Solutions 2CoreLab Partners Now Offers Semi-automated ECG Solutions 3Encision Reports 14% Revenue Increase in Second Quarter Results 2Encision Reports 14% Revenue Increase in Second Quarter Results 3Encision Reports 14% Revenue Increase in Second Quarter Results 4
(Date:12/25/2014)... December 25, 2014 Each year trauma ... 2 million hospital admissions across the nation (according to ... The CDC’s National Hospital Ambulatory Medical Care Survey ... survey conducted in 2010. They estimated that there were ... resulted in a primary diagnosis of broken bone or ...
(Date:12/24/2014)... December 24, 2014 Connie Casad, MD, ... functional medicine advocate with 30 years of practice experience ... evaluate the health benefits of dietary detoxification. The second ... participants following excellent results from test patients who just ... to explain her interest in conducting the study, Dr. ...
(Date:12/24/2014)... New York (PRWEB) December 24, 2014 ... http://www.xareltolawsuit2015.com/ ) that allege the blood thinner caused ... has outlined a leadership structure for the proceeding, ... dated December 17th, the Court plans to select ... parties and also plans on appointing a Plaintiffs’ ...
(Date:12/24/2014)... 25, 2014 BambooIndustry.com a famous bamboo ... years. Today, the company announces its multiple layer ... offer on these new products. , Bamboo panel is ... The multiple layer bamboo panel board features high quality ... and emissions free. The bamboo panel consists of multiple ...
(Date:12/24/2014)... Dec. 24, 2014 (HealthDay News) -- Adults who ... risk of migraine headaches, suggests a study published ... . "Childhood maltreatment can have long-lasting effects, ... in adulthood," study author Dawn Buse, director of ... York City, said in a journal news release. ...
Breaking Medicine News(10 mins):Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Bamboo Flooring Company Bambooindustry.com Introduces Its Multiple Layer Bamboo Panel Board Collection 2Health News:Abuse in Childhood Tied to Migraines in Adulthood 2
... The Rajasthan government will come up with a bill seeking ... centres in the state, State Health Minister Digambar Singh said ... special bill in the next assembly session to monitor all ... check activities against the interests of the state and its ...
... revealed that a genetic deficiency of an important enzyme can ... //. The enzyme is one of a class of enzymes ... to stop cells from dividing. ,The study, ... National Institute of Child Health and Human Development. The NIH ...
... At the Medicines Policy Summit a new report looked at ... 2006 //. ,In the last six years, 78 new ... was the equivalent of Pharmac. Of these medicines, 72 are ... funded by Pharmac. ,The report showed that ...
... say that Medicare's new prescription drug programme is progressing ... day and cutting costs for each beneficiary by an average ... Texas, the scenario is quite different. ,A lot ... drugs they need. Pharmacists who are plagued with ...
... Medical College Hospital, Kerala they removed a five-and-a-half inch-long scissors ... Akkooppoyil Achuthan aged 65 was admitted in the hospital for ... he was discharged but frequented the hospital complaining acute pain ... scissors in the stomach. ,They team of doctors ...
... Union health minister Anbumani Ramadoss has asked movie stars, ... soft drink products by endorsing them, in the interest ... a congregation of health experts on Friday at the ... stated that the celebrities should stay away from endorsing ...
Cached Medicine News:Health News:Genetic Link to Adrenal Tumor Revealed 2Health News:A Baffling New Drug Plan In Texas Town 2Health News:Ramadoss Urges Celebrities Not To Endorse Soft Drinks 2
Cleveland Bone Cutter #5, 17cm, 6-3/4"...
Beuse Zygomatic Arch Awl with slightly curved tip....
Steroid-eluting, single-pass lead. CapSure VDD2 optimizes VDD therapy and offers easier handling, proven performance, and choice....
Steroid eluting pacemaker leads...
Medicine Products: